These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35266253)

  • 1. Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.
    Maishi N; Sakurai Y; Hatakeyama H; Umeyama Y; Nakamura T; Endo R; Alam MT; Li C; Annan DA; Kikuchi H; Morimoto H; Morimoto M; Akiyama K; Ohga N; Hida Y; Harashima H; Hida K
    Cancer Sci; 2022 May; 113(5):1855-1867. PubMed ID: 35266253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
    J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
    Sakurai Y
    Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
    Sakurai Y; Hatakeyama H; Akita H; Harashima H
    Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.
    Yamamoto K; Ohga N; Hida Y; Maishi N; Kawamoto T; Kitayama K; Akiyama K; Osawa T; Kondoh M; Matsuda K; Onodera Y; Fujie M; Kaga K; Hirano S; Shinohara N; Shindoh M; Hida K
    Br J Cancer; 2012 Mar; 106(6):1214-23. PubMed ID: 22374465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.
    Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Harashima H
    Mol Ther; 2013 Jun; 21(6):1195-203. PubMed ID: 23568259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells.
    Hada T; Sakurai Y; Harashima H
    Pharmaceutics; 2015 Sep; 7(3):320-33. PubMed ID: 26389942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan.
    Maishi N; Ohba Y; Akiyama K; Ohga N; Hamada J; Nagao-Kitamoto H; Alam MT; Yamamoto K; Kawamoto T; Inoue N; Taketomi A; Shindoh M; Hida Y; Hida K
    Sci Rep; 2016 Jun; 6():28039. PubMed ID: 27295191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection.
    Yamamoto N; Sato Y; Munakata T; Kakuni M; Tateno C; Sanada T; Hirata Y; Murakami S; Tanaka Y; Chayama K; Hatakeyama H; Hyodo M; Harashima H; Kohara M
    J Hepatol; 2016 Mar; 64(3):547-55. PubMed ID: 26505121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
    Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
    J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core.
    Nakamura T; Yamada K; Fujiwara Y; Sato Y; Harashima H
    Mol Pharm; 2018 Jun; 15(6):2142-2150. PubMed ID: 29668291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
    Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
    Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property.
    Yamada K; Maishi N; Akiyama K; Towfik Alam M; Ohga N; Kawamoto T; Shindoh M; Takahashi N; Kamiyama T; Hida Y; Taketomi A; Hida K
    Int J Cancer; 2015 Dec; 137(12):2825-36. PubMed ID: 26100110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
    Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
    Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy.
    Endo R; Nakamura T; Kawakami K; Sato Y; Harashima H
    Sci Rep; 2019 Aug; 9(1):11335. PubMed ID: 31383907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR7: a novel tumor endothelial marker in renal cell carcinoma.
    Maishi N; Ohga N; Hida Y; Akiyama K; Kitayama K; Osawa T; Onodera Y; Shinohara N; Nonomura K; Shindoh M; Hida K
    Pathol Int; 2012 May; 62(5):309-17. PubMed ID: 22524658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modality of tumor endothelial VEGFR2 silencing-mediated improvement in intratumoral distribution of lipid nanoparticles.
    Yamamoto S; Kato A; Sakurai Y; Hada T; Harashima H
    J Control Release; 2017 Apr; 251():1-10. PubMed ID: 28192155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA.
    Liu X; Wang W; Samarsky D; Liu L; Xu Q; Zhang W; Zhu G; Wu P; Zuo X; Deng H; Zhang J; Wu Z; Chen X; Zhao L; Qiu Z; Zhang Z; Zeng Q; Yang W; Zhang B; Ji A
    Nucleic Acids Res; 2014 Oct; 42(18):11805-17. PubMed ID: 25223783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
    Cong L; Maishi N; Annan DA; Young MF; Morimoto H; Morimoto M; Nam JM; Hida Y; Hida K
    Breast Cancer Res; 2021 May; 23(1):51. PubMed ID: 33966638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.